B-Cell Diffuse Large B-Cell Lymphoma

In this video, Brian T. Hill, MD, PhD, discusses results of the phase 2 PILOT study of lisocabtagene maraleucel as second-line therapy for relapsed/refractory diffuse large B-cell lymphoma.

CHICAGO — Epcoritamab plus R-CHOP induced high complete metabolic response rates in previously untreated high-risk diffuse large B-cell lymphoma and double-hit or triple-hit lymphoma, according to research presented at ASCO Annual Meeting.

CHICAGO — Loncastuximab tesirine and polatuzumab vedotin may show improved efficacy and manageable toxicity in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, according to research presented at ASCO Annual Meeting.

NEW ORLEANS — Black adolescent and young adult patients with diffuse large B-cell lymphoma experienced worse overall outcomes in terms of mortality rate and survival compared with other races, according to a study.

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.

Despite a high upfront price, treatment with axicabtagene ciloleucel appeared more cost-effective as second-line therapy than standard treatment for relapsed or refractory large B-cell lymphoma, according to study results.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology & cellular therapy at the Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses a presentation from his group at ASH on the association between CAR T-cells and the cytopenia that commonly occur after therapy.